NATIONAL COMMUNITY PHARMACISTS ASSOCIATION for NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Alcohol and Drug Abuse ALC
Implementation of Public Law 114-198 pharmacy provisions; Implementation of Public Law 114-255 pharmacy provisions; H.R. 1854/S. 778, Prescription Drug Monitoring Act of 2017; S 892 / H.R. 4408, Opioid Addiction Prevention Act of 2017; HR 3528 / S.2460, Every Prescription Conveyed Securely Act; H.R. 3545, Overdose Prevention and Patient Safety Act; S. 1850, Protecting Jessica Grubbs Legacy Act; H.R. 1271, DXM Abuse Prevention Act of 2017; H.R. 1375, Prescriber Support Act of 2017; S. 523, Budgeting for Opioid Addiction Treatment Act; S. 581, Jessies Law; S 1079, Protecting Americans from Dangerous Opioids Act; H.R. 4236, MONITOR Act of 2017; H.R. 3991, Expanded Access to Opioid Abuse Treatment Act of 2017; H.R. 4275, Empowering Pharmacists in the Fight Against Opioid Abuse Act H.R. 5219, Opioid Prescription Verification Act of 2018 Draft legislation on suspension of payments for pharmacies suspected of fraud in Medicare Part D Draft legislation, Medicare Care Coordination Improvement Act of 2017 Draft legislation, Pain Care Coordination Act of 2018 S. 2456/H.R. 5311, CARA 2.0 Act of 2018 Discussion Draft of H.R. __, FDA Packaging and Disposal H.R. 5202, Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| SUSAN PILCH | — |
| KEVIN SCHWEERS | — |
Health Issues HCR
S. 469, Affordable and Safe Prescription Drug Importation Act; H.R. 1245, Affordable and Safe Prescription Drug Importation Act; H.R. 1776, Improving Access to Affordable Prescription Drugs Act; S. 771, Improving Access to Affordable Prescription Drugs Act; H.R. 242, Medicare Prescription Drug Price Negotiation Act of 2017; S. 41, Medicare Prescription Drug Price Negotiation Act of 2017; Drug Pricing Transparency
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| SUSAN PILCH | — |
| KEVIN SCHWEERS | — |
Medicare/Medicaid MMM
H.R. 1316, Prescription Drug Price Transparency Act; H.R. 1038, Improving Transparency and Accuracy in Medicare Part D Spending Act; S. 413, Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 592, Pharmacy and Medically Underserved Areas Enhancement Act; S. 109, Pharmacy and Medically Underserved Areas Enhancement Act; H.R.1939 - To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes; S.637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017; HR 394/ S 85, Restoring Access to Medication Act; HR 3921/S 1827, KIDS Act of 2017; HR 3271, Protecting Access to Diabetes Supplies Act of 2017; S. 870, Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017; Centers for Medicare and Medicaid Services (CMS) Proposed Rule for the 2019 Medicare Part D Plan Year, pharmacy provisions; S.2553, Know the Lowest Price Act of 2018; S.2554, Patient Right to Know Drug Prices Act; H.R. 5343, Prescription Transparency Act of 2018; Discussion draft, requiring plan sponsors to pass on revenue received from certain payments and adjustments to Medicare Part D enrollees; CMS Call Letter for 2019 Medicare Part D and Medicare Advantage Plans
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| SUSAN PILCH | — |
| KEVIN SCHWEERS | — |
Defense DEF
Tricare pharmacy working group
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| SUSAN PILCH | — |
| KEVIN SCHWEERS | — |
Budget/Appropriations BUD
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act; H.R. 2430 the FDA Reauthorization Act (FDARA) of 2017; S.934 FDA Reauthorization Act of 2017;
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| SUSAN PILCH | — |
| KEVIN SCHWEERS | — |
Animals ANI
Issues related to compounded pharmaceuticals for animals; H.R. 623, FairnesstoPetOwnersActof 2017
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| SUSAN PILCH | — |
| KEVIN SCHWEERS | — |
Pharmacy PHA
Congressional Oversight of 340 B Program; Issues related to FDA implementation of The Drug Quality and Security Act related to the regulations of pharmacy compounding; Biosimilar naming; H.R. 421 Allowing Greater Access to Safe and Effective Contraception Act; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017; HR 749, Lower Drug Costs through Competition Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILLIP ADAM HARBISON | — |
| RONNA HAUSER | — |
| KARRY LA VIOLETTE | — |
| SUSAN PILCH | — |
| KEVIN SCHWEERS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.